/ 0 1 2 3 4 5 6 2 7 4 0 1 8 6 9 : ; 6 7 : 0 9
0 1 8 6 9 : < 6 7 : 0 9 = 0 9 3 : 6 2 5 3 5 2 6 < 6 9 7 >
/ 5 2 7 8 5 < ? 9 3 4 5 : 7 < 0 1 8 6 9 : < 6 7 : 0 9
@ A B C D E F G H I E J G F D K G L D H K M E G @ I I N E G F B F D H O P Q R S T O R U R V W R X Y Z [ \
]
1 5 8 : 0 9 6 2 0 w w : x 5 w 0 1 5 ? 1 0 y 5
X ^ _ X ` R a b c P d e
z { | } ~ { | ~ } } { | }
f g h h h l
1 5 8 : 0 9 6 2 1 0 w 1 5 ? 1 0 y 6
R i j k R U P d Q
h f h h
m n
B @ E I B A I B E B J D I F G F I B E I
X e k R P a P a o p a Q R X a P Q e a P d e e X o a P Q e a
4
O R k P X Q V R a Q
h h l h h l
]
? 9 x = ¡
a Q X q e i j e U P d r i i P X
h t
n n
3 ¢ £ ¤ ¡ ¥ ¥ x ¦ § ¨ © § ª 3 § «
j X s r V R R X P [
7 ¬ ® ¯ ¯ ° ° ± ¥ ¥ ¥ ² w ³ ® ¯ ¯ ° ° ± ¥ ¥ ¡
h
5 ¬ ´ § µ ¶ ¨ §
[ Z [ Y u v P d d a a
l h
m
/ · ¸ ¨ ¦ ¹ ¹ ¶ ¶ ¶ ´ ¶ ¨ §
Q e a P
Ä
0 ´ § ´ §
9 º º § Å º º §
? § ¸ ; ¨ § : ¨ ; ¨ §
A » ¼ ½ ¾ ¿ ½ À » Á Â Ã F ¾ @ ¾ ¿ ½ À » Á Â Ã
]
O R P X X b c P d e Æ
Ç È É Ê Ë Ì Í Î Ï Ë Ð Ñ Ò Ó Ë Ô Ë Ì Õ Ö × Í Ì Ø Ù Ê Ð Í Î Ó È Ô Í Ú Ê Ú Ê Ò Ú È Ò Ú Ê Ì É Í Ì Ø Õ Ö × Ô Ð È Û È Ü Ô Ë Ò Ý Ð È
Ô Ð Ë Ô Ó Þ Î Í Ü Ê Ò ß à Ð á à â Ê Ì Ì Ë Ì á ã ä á á å æ Ë Ý Ì Ú Ð Ê È Ò Ë ç Ï Õ è á Ý Ð Ë Ô È Í Ì Ç È É Ê Ë Ì
é È Ð Î Ê Ì ê ë È Ð ì Í Ì Þ ê í í î í ï ð Í Ì Ý Í Ð Þ í ñ ò ó
g g l h g g g h ÷ h h h
n n m n
p P ô R Q R k d R P X R Q e a i e X V q e Q P Q Q R õ e X d o ö R P d Q b X ` P a P Q e a ø R ` e a P d b i i U R i e X X e k R
l g g h h g l g h h l h l h
n
k d P a Q e e d o Q R P W e ô R s V R a Q e a R o V R R Q a ` ù v R k X k e R e i Q R V R R Q a ` Q e X R ô R ú d P Q R Q R ô o R a U R Æ
û ü ý þ ý ÿ ý û û ý ý ý ü ý û ý ý ü ý û û û ý û
h g h l l h h l l h l h g
m m m m n m n
P a o X a Q R a e a s r U e a Q X R Æ U e a o R X a ` R P V k d R i X e V R d R U Q R o U e a Q X R a Q R
h g t h l g h
m n
õ ö b X e k R P a ø R ` e a ù v R R q e W c R U Q ô R e i Q R V R R Q a ` P X R S
h h l h l h h l h h l l h l h l h l
n
· v
l
n
e
l
X R
h
ô R ú R
h
Q a ` Q R
l
Q a `
l
k
l
X
P U Q U R a U e a Q X R P a o U e a o R X U e Q s R i i R U Q ô R Q X P Q R ` R i e X
Q P a P W d R a P Q e a P d X R k e a R
h l l l l l h l h l h h h l g l l
n n n n
· v e
l h
o U
U P d R k e i Q R Q a ` R X ô U R Æ a U d o a ` U e V V a Q q s W P R o P k k X e P U R P a o ö p R d i s
Q R Q a `
l l h h h h h g h
m m n
· v e k X e k e R V e o R d e i X V k d R V R a Q P Q e a P a o V e a Q e X a ` a Q R õ ö b X e k R P a ø R ` e a ù
h g l l h l h g
n n
r a e Q d a R e i Q R U e k R P a o k X k e R P a o k X e ô e a P d P ` R a o P P X R P Q Q P U R o ù
g t h l h h l g l l h h l l h h h
n m n n n
v R ú e X a ` d P a ` P ` R ú d d W R a ` d P a o ø P a ù j V d Q P a R e Q X P a d P Q e a ú d d W R k X e ô o R o ù
g g l h h h h h h h h g h
n n n n
p P ô R Q R k d R P X R a a ô Q a ` q e Q e a e V a P Q R i X e V q e X U e a Q X q e a R k P X Q U k P a Q S R Q R X P a P Q e a P d
h g h h l l l h h l h
n m
U e e X o a P Q e X e i Q R U e V V a U P W d R o R P R k X e ` X P V V R e X P a P Q e a P d R k R X Q a ö p Q R Q a ` P a o X ù
t h h h h l h h g l h
n í ñ È æ È ì È Ð í ñ ò n
p d e e i e X ú P X o Q e X R U R ô a ` q e X a e V a P Q e a W q Æ ` ô a ` Q R a P V R Æ i a U Q e a P d
h l h l l l g l h h l h l g g
n
Q Q d R P a o R V P d P o o X R R e i Q R o R ` a P Q R o U P a o o P Q R P Q q e X R P X d q U e a ô R a R a U R ù õ R P d d Q R a
h h g g h h g l l h h h l h
n n
U e V V a U P Q R ú Q Q R V o X R U Q d q P a o k X e ô o R Q R a R U R P X q o e U V R a Q P Q e a P a o P o V a Q X P Q ô R
h h
a i e X V P Q e a ù
l l l g h h h
n Ð á Î È Ì Í × Ë Ù æ Ð å Ì Ú Ë Ì Ò Ë Í Î È Ù Ò Ñ Ê Ò ]
d R P R P o o X R q e X X R k d q Q e Æ v R U a U P d b i i U R X P a o Æ R o U P d
h g h l h l h h h l l g h h
n n
b i i U R X i X e V Q R ^ e a Q v W R X U d e Æ ö p P a o ô X P d ö R k P Q Q X e ` X P V V R P a o R a o Q R a i e X V P Q e a Q e
g h g h g h h l g h h l g h l h
n
R X e ô ú e ù a Q ù v R P W e ô R V R a Q e a R o e i i U R X P X R Q R U a U P d i e U P d k e a Q i e X Q V R R Q a ` P a o V P q
l h h g h h h l h h l h l
n n n
P d e k X e ô o R q e ú Q V e X R o R Q P d R o a i e X V P Q e a ù e V P q R a o P o o Q e a P d R Q e a Q e
g h ÷ l t h l g h l h
ô e ô U R ú e ù a Q P a o V e P d R ô P ú e ù a Q X R k R U Q ô R d q ù
! " # $ % & ' ( ) * + , % - -
! .
t g h
n
õ R d e e i e X ú P X o Q e R P X a ` i X e V q e ù
h l
n
j a U R X R d q q e X Æ
ù ù
l
] n
O X P e o O P X P
f h f h h l l l
n
e e X o a P Q e X Æ e V V a U P W d R O R P R
h h l h g h l f h h l l l
m n
O ô e a e i ö R P d Q V R X ` R a U R P a o e V V a U P W d R O R P R
# $ % & ' (
) * + , - . /
- 4 - . 5 , 5 6 / . 7 5
0 1 2 3 2
8 9 : ; < 9 = > ? < 9 = @ A B > 9 ? B 9 C
4 E - - . F * 4 G / 6 H I / 5 7 H J * / 5 . 5 . 7 L . + / . 5 + - . 5 , M 7 - . 5 + - . N / 5 + O / . + H - . - 4 + - 5 , T 5 - 4 H
D 1 1 1 2 K 1 2 2 2 1 2 K 1 D 1 P 2 Q R 2 S Q Q 1
* * T O / / - V 5 W H W X W Y Z E 5 , , - . . H J 4 + . - 5
R 1 U 1 2
I [ J [ T . 7 / * . 6 H T O G 5 4 4 5 7 H / O 5 . / . + - 4 4 - . + \ / ] / * G , - J 4 + . - 5 + + \ / F . - + / 7 ^ 5 + - . 4 ) - /
D 1 1 0 2 1 0 1 D 2 2 Q K S 2 Q 2 2 2 Q Q S
5 . 7 + \ / - . + / . 5 + - . 5 , 6 5 . - _ 5 + - . 4 - . ` / . / 5 H M \ / O - . 7 * / + - + 5 . . / a Y b T H M I W Y X Z ` / . c / H
2 1 1 2 2 1 2 3 0 U R S 2 U 3
- + _ / , 5 . 7
R d 1
I [ J [ + f , O / H T O G 5 4 4 5 7 J a + 5 7 - . 5 5 . 7 , / . - + / . + - 5 H J O G 5 4 4 + \ / ] / * G , - J 4 + . - 5 H
D 1 D e 1 2 1 2 1 1 2 1 1 P 0 K 2 1 P P 2 Q K S 2 Q 2
/ 7 / - V 4 6 5 7 / W Z H h + \ , H W Y i j M / . \ 5 6 / . k H N / . O 5 V
g 1 1 Q 2 2 1 2 K 1
4 5 6 / ] / - . 5 H I / 5 7 I ) ) - / H I ) M * . + ) - / H J 4 + . - 5 H 5 , 7 - 4 V - ] 5 7 b W H W X i W m E 5 , , - . . H
D D 1 K 2 Q l Q Q S l 2 1 P Q Q S 2 0 2
J 4 + . - 5
2
! " !
WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ
REGIONAL OFFICE FOR EUROPE BUREAU RÉGIONAL DE L'EUROPE
WELTGESUNDHEITSORGANISATION ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
REGIONALBÜRO FÜR EUROPA ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО
Regional workshop on HIV and viral
Hepatitis testing and HIV pre-exposure
prophylaxis (PrEP) in non-EU/EEA
countries of the WHO European Region
Berlin, Germany 29 November 2018
22–23 January 2019 Original: English
OUTLINE
Background
HIV remains one of the most important public health challenges in the WHO European Region. The
WHO European Region is the only region worldwide where the number of new HIV infections is rising.
With more than 160 000 people newly diagnosed with HIV across the Region, this trend continued in
2016. One reason for this worrying trend: over half (51%) of the reported HIV diagnoses happen in a late
stage of infection. The eastern part of the Region is home to almost 80% of the new HIV diagnoses,
while late diagnosis is a common challenge observed across the whole WHO European Region, including
East, centre and West. If this trend persists, the Region will not be able to achieve the Sustainable
Development Goal target of ending the HIV epidemic by 2030.
Viral hepatitis is a public health threat that affects tens of millions in the WHO European Region, more
than two thirds of whom live in eastern Europe and central Asia. An estimated almost 170 000 people die
from causes related chronic hepatitis B and C in the Region every year. Although the disease burden
varies greatly between different parts of the Region, overall, only around 30% of people living with
chronic hepatitis C and less than 20% of those with chronic hepatitis B were diagnosed in 2015, lacking
behind the regional target of 50% diagnosed by 2020.
Overall, timely testing and diagnosis of HIV and viral hepatitis infections constitutes the largest gap in
the continuum of care.
Europe needs to focus on prioritizing effective and comprehensive prevention measures such as
awareness-raising; provision of needle exchange programmes and pre-exposure prophylaxis for HIV;
providing efficient HIV counselling and testing services, including rapid diagnostic services, community-
based HIV testing and HIV self-testing; and ensuring rapid access to quality treatment and care for those
diagnosed. Early diagnosis is important because it allows people to start HIV treatment sooner, which in
turn increases their chances of living a long and healthy life.
WHO recommends that all people at risk of hepatitis B and C should be offered testing services. People
diagnosed with chronic hepatitis B virus infection need to be regularly checked and assessed and offered
treatment when needed. New WHO hepatitis C guidelines recommend that all people diagnosed with
chronic hepatitis C should be offered treatment with DAAs. Countries in the European Region have
made substantial progress on prevention, but many of them need to scale up action towards universal
access to testing and treatment.
In September 2016, the 66th session of the Regional Committee of the WHO Regional Office for Europe
(RC66) has endorsed the Action plans for the health sector response to HIV and viral hepatitis in the
WHO European Region. The Action Plans guide Member States in accelerating the response to the HIV
and viral hepatitis epidemics at national levels and to contribute to the regional and global efforts to end
Outline
page 2
the HIV epidemic and eliminate viral hepatitis as a public health threat. The goals and targets are
supported by the 2030 Agenda for Sustainable Development, the multisectoral strategy for 2016–2021 of
the Joint United Nations Programme on HIV/AIDS, the Global Health Sector Strategies on HIV and
Viral Hepatitis for the period 2016–2021, and Health 2020, the European policy framework for health
and well-being. These global and regional strategic documents serve as a ground for accelerated policy
revisions in all Member States.
In addition, in 2015-2016 WHO released a set of normative guidelines1 and provides support to countries
in formulating and implementing policies and programmes to improve and scale up HIV and viral
hepatitis prevention, treatment, care and support services for all people in need. With latest scientific
developments, additional policy briefs and guidance were published in 2017-2018 namely, the guidelines
providing technical directions for effective and cost saving strategies for testing for HIV and specific
guidance on the use of antiretroviral medicines for HIV pre-exposure prophylaxis (PrEP).
As of September 2015, WHO recommends that people at substantial risk of HIV infection should be
offered PrEP as an additional prevention choice, as part of comprehensive prevention. Several countries
in the Region have implemented either pilot or full-scale PrEP programmes, and initial evidence is
becoming available that PrEP is highly effective not only on individual level, but also leads to reduction
of incidence of HIV infections. Other countries are requesting WHO technical support in rolling out and
implementation of PrEP programmes.
In 2017 WHO published its first Guidelines on hepatitis B and C testing outlining the public health
approach to strengthening and expanding current testing practices for HBV and HCV, and are intended
for use across age groups and populations.
Strategic documents complemented with the WHO guidelines assist countries in taking action,
strengthening and simplifying national policies and practices assuring evidence-based approach aligned
with most up to date scientific evidence within national programmes. Across the WHO European Region,
there should be a renewed focus on ensuring the cost efficiency, quality and effectiveness of existing
HIV and viral hepatitis services and the financial sustainability of the response. To date, some Member
States took prompt actions and developed or updated their national policies for HIV and viral hepatitis
testing. Other countries still plan to do so.
Scope and purpose
The meeting is aimed at reviewing the countries’ progress, challenges and exchange good practices to
overcome them in the field of HIV and viral hepatitis testing, as well as discuss the latest evidence and
progress in implementation of PrEP in the WHO European Region. The following areas will be covered
during the meeting:
• HIV and viral hepatitis testing strategies and practices in the non EU-EEA countries and
beyond, including latest and most innovative approaches
• HIV and viral hepatitis testing services scale up and strengthening linkage to care to enable
better access to treatment, through expanded community-based approaches and HIV self-testing
• Cost effectiveness of testing strategies for an accelerated and maintained response of national
programs
• PrEP roll-out, implementation and monitoring in the Member States of the WHO European
Region
1
(1) Consolidated guidelines on HIV testing services and latest Guidelines on HIV self-testing and partner notification; (2) Consolidated
guidelines on the use of antiretroviral drugs for treating and preventing HIV infection; (3) Consolidated strategic information guidelines for
HIV in the health sector; (4) Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations (2016 update)
Outline
page 3
Objectives
1. Overview HIV and viral hepatitis testing strategies and practices used in the WHO European Region;
2. Exchange information on innovative approaches in HIV and hepatitis testing and PrEP
implementation, discuss relevant national strategies and their financing;
3. Review the latest evidence, WHO guidance, tools and policies;
4. Address cross-cutting issues and opportunities, particularly in regard to access to services for
vulnerable populations.
Expected results and Outputs
• A comprehensive overview of national testing strategies and updated policies in the participating
countries
• Participants briefed and exchanged information on the latest evidence and good practices in the
field of HIV and viral hepatitis testing and PrEP implementation
• A report from the WHO Regional Consultation describing the outcomes of the meeting
Event Format
The meeting is envisaged as an extended forum of partners and leading experts that will consist of plenary
sessions, poster session and parallel working groups on defined topics. The agenda will be developed to
align with latest developments in science and public health but also responds to the needs of countries
invited to the meeting
The event will be followed by a series of actions in countries, namely policy revisions of possible
demonstration projects which is subject to agreements with countries and availability of national and
external resources.
Participants
The areas proposed for discussions may need coordinated efforts from all sectors of society to assure
appropriate follow up of actions in countries. Therefore, WHO intends to invite to this meeting Member
States, non-state actors— including civil society and community-based organizations, research and
academic institutions, healthcare providers, federal, district, municipal level governing bodies, media,
and others.
Participants include:
• Representatives of Member States from non EU/EEA countries and other selected countries in the
HO European Region, stakeholders and national experts on PrEP and testing services;
• Representatives of UNAIDS and co-sponsors, ECDC, Global Fund, CDC/PEPFAR and other
organizations active in the Region
• Representatives from WHO Country Offices, Regional Offices and Headquarters
• Civil society organisations, professional associations and WHO Collaborating Centres
WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ
REGIONAL OFFICE FOR EUROPE BUREAU RÉGIONAL DE L'EUROPE
WELTGESUNDHEITSORGANISATION ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
REGIONALBÜRO FÜR EUROPA ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО
Regional workshop on HIV and viral
Hepatitis testing and HIV pre-exposure
prophylaxis (PrEP) in non-EU/EEA
countries of the WHO European Region
Berlin, Germany 29 November 2018
22–23 January 2019 Original: English
Provisional agenda
Day 1 – Tuesday 22 January 2019
9:00–10:00 Plenary session 1
Welcome remarks
Scene setter presentations
10:00–12:30 Poster session or panel sessions
Counties to present their progress and plans for PrEP implementation
12:30–13:30 Lunch
13:30–14:30 Plenary session 2
Good examples and practices from the Region and applicability in other countries
14:30–17:00 Countries group work
Report back and plans for next steps
Day 2 – Wednesday 23 January 2019
9:00–10:30 Plenary session 3
• Overview of HIV, HCV, HBV testing strategies used in European region
• WHO recommendations on HIV, HCV, HBV testing strategies, validation of
testing algorithms, monitoring performance
• Systematic review of the use of Western blot and immunoblotting for accurate
HIV diagnosis
10:30–12:30 Group work
12:30–13:30 Lunch
13:30–14:30 Plenary session 4
• Overview of HIV self-testing policies in the European region
WHO recommendation on HIV self-testing product selection and monitoring
performance
14:30–17:00 Group work. Adjourn
Saatja: Jürgen Ojalo <
[email protected]>
Saadetud: 10.12.2018 09:32
Adressaat: Mall Hiet <
[email protected]>
Teema: FW: WHO Regional Workshop on HIV and viral hepatitis testing and HIV pre-exposure
prophylaxis (PrEP) - nomination request CRM:0056802
Manused: HIV HEP PrEP_EST.pdf; Outline.pdf; Provisional agenda.pdf
Palun registreeri, kui see kuskilt teist teed pidi juba tulnud pole.
Jürgen
From: Olga Fradkina [mailto:
[email protected]]
Sent: Friday, December 7, 2018 7:23 PM
To: Jürgen Ojalo <
[email protected]>
Cc: Andre Pung <
[email protected]>; Marge Reinap <
[email protected]>; Märt Volmer
<
[email protected]>; Triin Uusberg <
[email protected]>
Subject: WHO Regional Workshop on HIV and viral hepatitis testing and HIV pre-exposure prophylaxis
(PrEP) - nomination request CRM:0056802
Please see the attached correspondence sent from the World Health Organization, Regional
Office for Europe. One or more attachments may be included.
Veuillez vous référer à la correspondance ci-jointe du Bureau régional de l'Europe de
l'Organisation mondiale de la santé. Une ou plusieurs annexes peuvent être jointes.
Mit der Bitte um Kenntnisnahme der beiliegenden Korrespondenz (eine oder mehrere Anlagen),
Weltgesundheitsorganisation, Regionalbüro für Europa
См. прикрепленные письма от Европейского регионального бюро Всемирной организации
здравоохранения (один или несколько прикрепленных файлов).